Gulf International Bank UK Ltd boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 0.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 45,100 shares of the life sciences company’s stock after buying an additional 60 shares during the period. Gulf International Bank UK Ltd’s holdings in Illumina were worth $7,825,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in ILMN. Vanguard Group Inc. raised its stake in shares of Illumina by 3.0% in the first quarter. Vanguard Group Inc. now owns 9,648,842 shares of the life sciences company’s stock valued at $1,646,479,000 after buying an additional 285,379 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Illumina by 69.0% in the first quarter. Jennison Associates LLC now owns 5,254,274 shares of the life sciences company’s stock valued at $896,589,000 after buying an additional 2,144,576 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Illumina by 8.0% in the first quarter. Geode Capital Management LLC now owns 1,458,071 shares of the life sciences company’s stock valued at $248,460,000 after buying an additional 107,941 shares in the last quarter. TIAA CREF Investment Management LLC raised its position in Illumina by 40.1% in the first quarter. TIAA CREF Investment Management LLC now owns 948,121 shares of the life sciences company’s stock worth $161,787,000 after buying an additional 271,461 shares in the last quarter. Finally, Legal & General Group Plc raised its position in Illumina by 3.9% in the first quarter. Legal & General Group Plc now owns 651,314 shares of the life sciences company’s stock worth $111,142,000 after buying an additional 24,613 shares in the last quarter. Hedge funds and other institutional investors own 93.81% of the company’s stock.
Shares of Illumina, Inc. (NASDAQ ILMN) opened at 199.23 on Thursday. Illumina, Inc. has a 1-year low of $119.37 and a 1-year high of $199.95. The firm’s 50-day moving average is $178.82 and its 200 day moving average is $173.34. The stock has a market capitalization of $29.09 billion, a P/E ratio of 39.97 and a beta of 0.83.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.14. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The business had revenue of $662 million during the quarter, compared to analyst estimates of $642.38 million. During the same period in the previous year, the firm earned $0.86 EPS. Illumina’s quarterly revenue was up 10.3% compared to the same quarter last year. On average, analysts expect that Illumina, Inc. will post $3.65 EPS for the current fiscal year.
WARNING: This piece was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://stocknewstimes.com/2017/08/10/gulf-international-bank-uk-ltd-boosts-stake-in-illumina-inc-nasdaqilmn-updated-updated.html.
A number of research analysts have commented on ILMN shares. Piper Jaffray Companies restated an “overweight” rating and issued a $187.00 price objective (up from $170.00) on shares of Illumina in a research note on Friday, April 14th. Vetr raised shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $196.75 target price on the stock in a report on Monday, April 17th. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a report on Thursday, April 13th. Cantor Fitzgerald lifted their target price on shares of Illumina from $155.00 to $170.00 and gave the company a “neutral” rating in a report on Wednesday, April 26th. Finally, BidaskClub raised shares of Illumina from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company’s stock. Illumina presently has a consensus rating of “Hold” and a consensus price target of $177.01.
In other Illumina news, EVP Omead Ostadan sold 1,671 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $195.26, for a total transaction of $326,279.46. Following the completion of the transaction, the executive vice president now owns 24,571 shares of the company’s stock, valued at approximately $4,797,733.46. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $184.75, for a total value of $26,788.75. Following the transaction, the senior vice president now directly owns 10,791 shares of the company’s stock, valued at approximately $1,993,637.25. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 134,010 shares of company stock valued at $23,946,015. Insiders own 1.60% of the company’s stock.
About Illumina
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
